1071517-82-2

Basic information

• Product Name: (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one
• Synonyms: (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one
• CAS NO: 1071517-82-2
• Molecular Weight: 593.417
• Mol File: 1071517-82-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one(1071517-82-2)
• EPA Substance Registry System: (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one(1071517-82-2)

Safety Data

• Hazardous Substances Data: 1071517-82-2(Hazardous Substances Data)

Upstream product

• 1000312-85-5 (7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[e][1,2,4]thiadiazin-3-yl)-acetic acid 
• 1071520-41-6 (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 105786-35-4 (rac-di-exo)-3-amino-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 95630-75-4 ethyl exo-3-aminobicyclo<2.2.1>heptane-2-exo-carboxylate hydrochloride 
• 179462-36-3 (±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 
• 7486-95-5 exo-3-azatricyclo<4.2.1.0^2,5>nonan-4-one 
• 1071520-32-5 (1S,2S,3R,4R)-3-ethoxycarbonyl-bicyclo[2.2.1]hept-2-yl-ammonium (1'S)-(+)-10-camphorsulfonate 
• 498-66-8 norborn-2-ene 
• 459-57-4 4-fluorobenzaldehyde 
• 785027-31-8 (1R,2R,3S,4S)-3-amino-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 109-02-4 4-methyl-morpholine 
• 200731-31-3 HATU 

Downstream Products

• 1198470-54-0 (1R,2S,7R,8S)-3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazine-7-carbonitrile 
• 1071518-42-7 cyclopropanesulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}amide 
• 1071518-09-6 (1R,2S,7R,8S)-5-[7-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 1071517-85-5 (1R,2S,7R,8S)-5-[7-(1,1-dioxo-4,5-dihydro-1H-1λ6-thiophen-2-yl)-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 1071517-89-9 (1R,2S,7R,8S)-5-[7-(1,1-dioxotetrahydro-1λ6-thiophen-2-yl)-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 1071521-45-3 (1R,2S,7R,8S)-5-(7-azido-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 1071518-23-4 (1R,2S,7R,8S)-5-(7-amino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 1071522-41-2 benzyl [N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}sulfamoyl]carbamate 
• 1071519-14-6 (1R,2S,7R,8S)-N-{3-[-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}sulfamide 
• 1071519-10-2 pyridine-3-sulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}amide 

Relevant articles and documents

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID

The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.